<DOC>
	<DOC>NCT03074058</DOC>
	<brief_summary>The primary objective of this study was to establish the bioequivalence of two different tablet formulations containing BAY77-1931. The secondary objectives of this study were to assess the safety and tolerability, as well as to Investigate the plasma lanthanum concentration after BAY 77-1931 ODT 500 mg administration.</brief_summary>
	<brief_title>Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet</brief_title>
	<detailed_description />
	<criteria>Japanese healthy male adult volunteers (age, 2045 years; BMI, 17.626.4 kg/m2) Regular use of medicines including Chinese herbal drugs Clinically relevant findings in the physical examination Subject who cannot take the study drug appropriately (e.g. weak biting force, insufficient salivary flow)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>